Trial Profile
A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pegfilgrastim
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 29 Sep 2021 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
- 08 Jun 2021 Results (n=40) reporting efficacy and safety from phase II portion of this simon 2 stage trial presented at the 57th Annual Meeting of the American Society of Clinical Oncology